论文部分内容阅读
The first generation direct antiviral agents(DAAs) highlighted substantial prognosis improvement among liver transplant(LT) candidates and recipients with recurrent hepatitis C virus(HCV) infection. During2014, second generation DAAs are associated with high sustained virological response rates(> 95%), shortened duration courses and relatively few toxicities. In keeping with the currently available data, patients with decompensated cirrhosis awaiting LT is preferable to be treated with interferon-free, new generation DAAs, with or without ribavirin combinations. Although data about the safety of new DAAs combinations in this patient population are limited, sofosbuvir and daclatasvir pharmacokinetics do not appear to change significantly in moderate or severe liver impairment, while other new DAAs(simeprevir, asunaprevir) seem to be contraindicated in patients with severe liver impairment(Child-Pugh class C). On the other hand, sofosbuvir should not be given in patients with glomerular filtration rate ≤ 30 m L/min, but ongoing trials will clarify better this issue. With the objective that newer antiviral combinations will yield safer and more efficient manipulation of HCV recurrence posttransplant, the European Association for the Study of the Liver has recently updated its recommendations towards this direction. Nevertheless the new antivirals’ high cost may be the biggest challenge to their implementation worldwide.
The first generation direct antiviral agents (DAAs) highlight substantial prognosis improvement among liver transplant (LT) candidates and recipients with recurrent hepatitis C virus (HCV) infection. During 2014, second generation DAAs are associated with high sustained virological response rates (> 95% , shortened duration courses and relatively few toxicities. In keeping with the currently available data, patients with decompensated cirrhosis awaiting LT is preferable to be treated with interferon-free, new generation DAAs, with or without ribavirin combinations. DAAs combinations in this patient population are limited, sofosbuvir and daclatasvir pharmacokinetics do not appear to change significantly in moderate or severe liver impairment, while other new DAAs (simeprevir, asunaprevir) seem to be contraindicated in patients with severe liver impairment (Child-Pugh class On the other hand, sofosbuvir should not be given in patients with glomerular With the objective that newer antiviral combinations will yield safer and more efficient manipulation of HCV recurrence posttransplant, the European Association for the Study of the Liver has recently updated its Suggestions the this direction. Nevertheless the new antivirals’ high cost may be the biggest challenge to their implementation worldwide.